English Global
New Delhi, India, December 14, 2023: Panacea Biotec, one of India’s leading biotechnology company is happy to announce the launch of world’s first fully-liquid wP-IPV based Pentavalent vaccine, EasyFourPol®, in India and registration of Valganciclovir 50 mg/ml Powder for Oral Solution by its step-down wholly-owned subsidiary company viz. Panacea Biotec Germany GmbH, in Germany.
EasyFourPol® is the world’s first fully liquid wP-IPV Pentavalent vaccine. wP-IPV Pentavalent vaccine protects children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b.
EasyFourPol® is a ready-to-use combination vaccine that does not require preparation by healthcare workers at the clinic. It achieves the same level of protection as immunized with single-antigen vaccines, reduces the number of visits to vaccination centres, and reduces the overall cost of immunisation for all stakeholders. It leads to less vaccination and lesser shots for the child and greater comfort for the parents while ensuring better compliance for healthcare practitioners. Fewer shots also mean time saved for parents and more efficiency at points of vaccination. Additionally, it also helps reduce carbon emissions by reducing the need for vials, syringes, packaging material, and visits to vaccine administration centres.
For healthcare practitioners who follow Indian Academy of Paediatrics’ (IAP) recommended Immunisation schedule, EasyFourPol® offers a credible option for booster dose. EasyFourPol® has an addressable market size of INR 51 crore in India.
Paediatric vaccination plays an important role to achieve Sustainable Development Goals (SDGs) set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births.
Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec,said, “We are delighted to launch EasyFourPol® – another landmark in our innovative and first-in-class combination vaccine portfolio that makes vaccinations easier, benefits the child, parents, and doctors while helping the world meet UN Sustainable Development Goals. We are certain that Indian paediatricians and parents will continue to put their trust in Panacea Biotec to meet ever-growing vaccination needs through innovative solutions.”
Panacea Biotec Germany GmbH, a step-down wholly owned subsidiary of Panacea Biotec, is excited to announce registration of Valganciclovir 50 mg/ml Powder for Oral Solution in Germany. It competes in a €1 million market (as per IQVIA). The medication is a deoxynucleoside analogue cytomegalovirus DNA polymerase inhibitor indicated for:
●the initial and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).
●the prophylaxis of CMV disease in CMV-negative adults and children (from birth and up to 18 years of age) who have received an organ transplant from a CMV-positive donor.
Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec,further said, “In continuation of our belief to broaden our focus while continuing our therapy focus – Valganciclovir Powder for Oral Solution is a welcome addition to our transplant portfolio in Germany. We look forward to scaling up our operations and continue to build trust with healthcare practitioners as a high-quality sustainable supplier of medicines for transplant care.”
***
About Panacea Biotec
Panacea Biotec is a leading pharmaceutical and biotechnology company with established research, manufacturing and marketing capabilities. Panacea Biotec has pioneered in the development of innovative fully-liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. We have also launched the world's first fully liquid wP-IPV based hexavalent vaccine EasySix™ (DTwP-HepB-Hib-IPV) in India in March 2017. EasySix™ helps reduce carbon emissions by over 60% by reducing the number of vials, syringes required for immunisation and eliminating the need to transport multiple vaccines under cold-chain across the world. In October 2021, WHO SAGE announced global rollout of wP-IPV based Hexavalent vaccines. Panacea Biotec is the innovator for wP-IPV based Hexavalent vaccine called EasySix™. It has been marketed in India since 2017 and is the leading vaccine in its segment. EasySix™ also features in the Top 500 Brands of India as per IMS IQVIA and AIOCD. Our vaccines are manufactured in WHO Prequalified Facilities that had recently received Closure of Inspection from the WHO PQ team in September 2023.
The key vaccines in portfolio are EasySix™(DTwP-Hib-HepB-IPV), EasyFive-TT™(DTwP-Hib-HepB), EasyFour-TT™(DTwP-Hib), EasyFourPol® (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Panacea Biotec’s pipeline vaccines include NucoVac®11 (Pneumococcal Conjugate Vaccine), DengiALL® (Recombinant Tetravalent Dengue Candidate Vaccine) and Td (tetanus and diphtheria – reduced).
Panacea Biotec remains focused on merging cutting-edge science and technology with an unwavering commitment towards unmet medical needs while ensuring affordability. It has research collaborations with leading national and international research organizations and corporations. Panacea Biotec has around 2,000 employees.
For more information, visit:www.panaceabiotec.com Follow our news page for the latest updates. Follow us via @PanaceaBiotec and LinkedIn.
****
For more information:
For Investors
Mr. Amit Saraswat
AGM - Finance
Tel: + 91-11-41679000 Ext. 2401, 41578055 (Direct)
Mobile: +91 9811156788
Email:amitsaraswat@panaceabiotec.com
For Media
Mr. P. D. Karan
Vice President - Corporate Communication & Business Development
Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)
Mobile: + 91 9312693040, + 91 9810500539
Email:pdkaran@panaceabiotec.com